Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Trunk muscle dysfunction in patients with myotonic dystrophy type 2 and its contribution to chronic low back pain

D. Vlazna, P. Krkoska, M. Sladeckova, O. Parmova, T. Barusova, K. Hrabcova, S. Vohanka, K. Matulova, B. Adamova

. 2023 ; 14 (-) : 1258342. [pub] 20231026

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23022648

INTRODUCTION: Myotonic dystrophy type 2 (MD2) presents with a varied manifestation. Even though the myopathy in these patients is more widespread, axial musculature involvement is one of the most prominent conditions. MD2 patients also often report chronic low back pain (CLBP). The purpose of this study was to evaluate trunk muscle function, including respiratory muscles, in patients with MD2 and to compare it with healthy controls, to determine the occurrence of CLBP in patients with MD2, and to assess whether trunk muscle dysfunction increases the risk of CLBP in these patients. METHODS: We enrolled 40 MD2 patients (age range 23 to 76 years, 26 women). A comprehensive battery of tests was used to evaluate trunk muscle function. The tests consisted of quantitative muscle strength testing of low back extensor muscles and respiratory muscles and the assessment of trunk muscle endurance. A neurological evaluation contained procedures assessing the distribution of muscle weakness, myotonia, and pain, and used questionnaires focused on these items and on disability, depression, and physical activity. RESULTS: The results of this study suggest that patients with MD2 show significant dysfunction of the trunk muscles, including the respiratory muscles, expressed by decreased muscle strength and endurance. The prevalence of CLBP in patients with MD2 was 52.5%. Based on our analysis, the only independent significant risk factor for CLBP in these patients was maximal isometric lower back extensor strength in a prone position ≤ 15.8 kg (OR = 37.3). Other possible risk factors were severity of myotonia and reduced physical activity. CONCLUSION: Outcomes of this study highlighted the presence of axial muscle dysfunction, respiratory muscle weakness, and frequent occurrence of CLBP together with its risk factors in patients with MD2. We believe that the findings of this study may help in management and prevention programs for patients with MD2.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022648
003      
CZ-PrNML
005      
20240117120931.0
007      
ta
008      
240105s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fneur.2023.1258342 $2 doi
035    __
$a (PubMed)37954643
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vlazna, Daniela $u Department of Neurology, Center for Neuromuscular Diseases (Associated National Center in the European Reference Network ERN EURO-NMD), University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Rehabilitation, University Hospital Brno, Brno, Czechia
245    10
$a Trunk muscle dysfunction in patients with myotonic dystrophy type 2 and its contribution to chronic low back pain / $c D. Vlazna, P. Krkoska, M. Sladeckova, O. Parmova, T. Barusova, K. Hrabcova, S. Vohanka, K. Matulova, B. Adamova
520    9_
$a INTRODUCTION: Myotonic dystrophy type 2 (MD2) presents with a varied manifestation. Even though the myopathy in these patients is more widespread, axial musculature involvement is one of the most prominent conditions. MD2 patients also often report chronic low back pain (CLBP). The purpose of this study was to evaluate trunk muscle function, including respiratory muscles, in patients with MD2 and to compare it with healthy controls, to determine the occurrence of CLBP in patients with MD2, and to assess whether trunk muscle dysfunction increases the risk of CLBP in these patients. METHODS: We enrolled 40 MD2 patients (age range 23 to 76 years, 26 women). A comprehensive battery of tests was used to evaluate trunk muscle function. The tests consisted of quantitative muscle strength testing of low back extensor muscles and respiratory muscles and the assessment of trunk muscle endurance. A neurological evaluation contained procedures assessing the distribution of muscle weakness, myotonia, and pain, and used questionnaires focused on these items and on disability, depression, and physical activity. RESULTS: The results of this study suggest that patients with MD2 show significant dysfunction of the trunk muscles, including the respiratory muscles, expressed by decreased muscle strength and endurance. The prevalence of CLBP in patients with MD2 was 52.5%. Based on our analysis, the only independent significant risk factor for CLBP in these patients was maximal isometric lower back extensor strength in a prone position ≤ 15.8 kg (OR = 37.3). Other possible risk factors were severity of myotonia and reduced physical activity. CONCLUSION: Outcomes of this study highlighted the presence of axial muscle dysfunction, respiratory muscle weakness, and frequent occurrence of CLBP together with its risk factors in patients with MD2. We believe that the findings of this study may help in management and prevention programs for patients with MD2.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Krkoska, Peter $u Department of Neurology, Center for Neuromuscular Diseases (Associated National Center in the European Reference Network ERN EURO-NMD), University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Sladeckova, Michaela $u Department of Neurology, Center for Neuromuscular Diseases (Associated National Center in the European Reference Network ERN EURO-NMD), University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia $u Department of Rehabilitation, University Hospital Brno, Brno, Czechia $u Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Parmova, Olesja $u Department of Neurology, Center for Neuromuscular Diseases (Associated National Center in the European Reference Network ERN EURO-NMD), University Hospital Brno, Brno, Czechia
700    1_
$a Barusová, Tamara $u Institute of Biostatistics and Analyses Ltd., Brno, Czechia $7 xx0312819
700    1_
$a Hrabcova, Karolina $u Institute of Biostatistics and Analyses Ltd., Brno, Czechia
700    1_
$a Vohanka, Stanislav $u Department of Neurology, Center for Neuromuscular Diseases (Associated National Center in the European Reference Network ERN EURO-NMD), University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Matulova, Katerina $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Adamova, Blanka $u Department of Neurology, Center for Neuromuscular Diseases (Associated National Center in the European Reference Network ERN EURO-NMD), University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
773    0_
$w MED00174552 $t Frontiers in neurology $x 1664-2295 $g Roč. 14, č. - (2023), s. 1258342
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37954643 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240117120927 $b ABA008
999    __
$a ok $b bmc $g 2036351 $s 1209093
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 14 $c - $d 1258342 $e 20231026 $i 1664-2295 $m Frontiers in neurology $n Front. neurol. $x MED00174552
LZP    __
$a Pubmed-20240105

Najít záznam

Citační ukazatele

Možnosti archivace